American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(suppl 1):S98-S110. doi:10.2337/dc20-S009
2.
ConwayBMillerRGCostacouT, et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med. 2010;27(4):398-404. doi: 10.1111/j.1464-5491.2010.02956.x. PMID: 20536510; PMCID:PMC3129711
3.
FureyKWilkinsK.Prescribing “off-label”: what should a physician disclose?AMA J Ethics. 2016;18(6):587-593. doi:10.1001/journalofethics.2016.18.6.ecas3-1606
4.
HarrisKBolandCMeadeLBattiseD.Adjunctive therapy for glucose control in patients with type 1 diabetes. Diabetes Metab Syndr Obes. 2018;11:159-173. doi:10.2147/DMSO.S141700
5.
Hill-BriggsFAdlerNEBerkowitzSA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2021;44(1):258-279. doi:10.2337/dci20-0053
6.
HillJNielsenMFoxMH.Understanding the social factors that contribute to diabetes: a means to informing health care and social policies for the chronically ill. Perm J. 2013;17(2):67-72. doi:10.7812/TPP/12-099
IsaacsDYagerSParkerMWolfeLLuxenburgJLekicS.Adjunct antihyperglycemic agents in overweight and obese adults with type 1 diabetes. Ann Pharmacother. 2019;53(4):371-384. doi:10.1177/1060028018816728
9.
KarrasSNKoufakisTZebekakisPKotsaK.Pharmaco-logic adjunctive to insulin therapies in type 1 diabetes: the journey has just begun. World J Diabetes. 2019;10(4):234-240. doi:10.4239/wjd.v10.i4.234
MottalibAKasettyMMarJYElseaidyTAshrafzadehSHamdyO.Weight management in patients with type 1 diabetes and obesity. Curr Diab Rep. 2017;17(10):92. doi:10.1007/s11892-017-0918-8
